Jubilant Ingrevia Ltd
Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.
Jubilant Ingrevia’s portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis. [1]
- Market Cap ₹ 11,065 Cr.
- Current Price ₹ 694
- High / Low ₹ 885 / 500
- Stock P/E 44.0
- Book Value ₹ 184
- Dividend Yield 0.72 %
- ROCE 11.1 %
- ROE 8.87 %
- Face Value ₹ 1.00
Pros
- Company has been maintaining a healthy dividend payout of 33.5%
Cons
- Stock is trading at 3.78 times its book value
- Company has a low return on equity of 9.24% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Part of BSE 500 Nifty 500 BSE SmallCap BSE Allcap BSE Commodities
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
0 | 684 | 4,949 | 4,773 | 4,136 | 4,178 | |
0 | 567 | 4,108 | 4,224 | 3,708 | 3,659 | |
Operating Profit | -0 | 117 | 841 | 549 | 427 | 519 |
OPM % | 17% | 17% | 11% | 10% | 12% | |
0 | -10 | 22 | 32 | 29 | 38 | |
Interest | 0 | 7 | 31 | 22 | 53 | 56 |
Depreciation | 0 | 22 | 123 | 122 | 136 | 158 |
Profit before tax | -0 | 77 | 709 | 437 | 268 | 344 |
Tax % | 0% | 30% | 33% | 30% | 32% | 27% |
-0 | 54 | 477 | 308 | 183 | 251 | |
EPS in Rs | -3.40 | 3.41 | 29.93 | 19.31 | 11.48 | 15.77 |
Dividend Payout % | 0% | 10% | 17% | 26% | 43% | 31% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -5% |
TTM: | 1% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 331% |
3 Years: | -20% |
TTM: | 34% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 13% |
1 Year: | 35% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 12% |
3 Years: | 9% |
Last Year: | 9% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Equity Capital | 0.05 | 16 | 16 | 16 | 16 | 16 |
Reserves | -0 | 1,907 | 2,417 | 2,650 | 2,722 | 2,911 |
0 | 556 | 238 | 407 | 740 | 764 | |
0 | 888 | 1,111 | 1,176 | 1,241 | 1,341 | |
Total Liabilities | 0 | 3,366 | 3,782 | 4,249 | 4,719 | 5,032 |
0 | 1,805 | 1,798 | 1,846 | 2,539 | 2,581 | |
CWIP | 0 | 65 | 174 | 525 | 331 | 525 |
Investments | 0 | 50 | 6 | 8 | 15 | 37 |
0 | 1,446 | 1,804 | 1,870 | 1,834 | 1,889 | |
Total Assets | 0 | 3,366 | 3,782 | 4,249 | 4,719 | 5,032 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
0 | 112 | 453 | 462 | 430 | 508 | |
0 | 33 | -71 | -469 | -568 | -393 | |
0 | -72 | -418 | 42 | 144 | -129 | |
Net Cash Flow | 0 | 73 | -36 | 35 | 6 | -13 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Debtor Days | 251 | 43 | 39 | 50 | 53 | |
Inventory Days | 601 | 117 | 146 | 160 | 163 | |
Days Payable | 685 | 103 | 113 | 131 | 141 | |
Cash Conversion Cycle | 167 | 57 | 72 | 80 | 75 | |
Working Capital Days | 269 | 59 | 61 | 64 | 65 | |
ROCE % | 8% | 29% | 16% | 10% | 11% |
Documents
Announcements
-
Certificate Under Chapter XVII Of SEBI Operational Circular Dated 22Nd May 2024, As Amended
6 Jun - Jubilant Ingrevia redeemed Rs. 100 Cr Commercial Paper on 06.06.2025 as scheduled.
-
Intimation Of Repayment Of Commercial Paper (CP)
6 Jun - Jubilant Ingrevia redeemed Rs. 100 Cr commercial paper on June 6, 2025 maturity date.
-
Intimation Of Record Date For Maturity Of Commercial Papers
6 Jun - Record date July 30, 2025 for Rs. 100 Cr commercial paper maturing July 31, 2025.
-
Announcement under Regulation 30 (LODR)-Issue of Securities
6 Jun - Issued Rs. 100 Cr commercial papers at 6.3% for 55 days, total CPs outstanding Rs. 150 Cr.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - Annual Secretarial Compliance Report filed for FY 2024-25 as per SEBI regulations.
Annual reports
Concalls
-
May 2025Transcript PPT REC
-
Mar 2025Transcript PPT
-
Jan 2025Transcript PPT REC
-
Oct 2024TranscriptPPT
-
Oct 2024Transcript PPT
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Jul 2023Transcript PPT REC
-
Jul 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022TranscriptPPT
-
Mar 2022TranscriptNotesPPT
-
Mar 2022TranscriptNotesPPT
-
Feb 2022TranscriptPPT
-
Oct 2021TranscriptNotesPPT
-
Sep 2021TranscriptNotesPPT
-
Aug 2021TranscriptPPT
-
Jun 2021Transcript PPT
-
May 2021TranscriptPPT
Leadership[1]
# 40+ years of legacy in Chemicals space, started in 1978
# Global player in Pyridine + Beta, Vitamin B3 and Acetic Anhydride.
# Serves 15 of the top 20 Global Pharma & 7 of the top 10 Global Agrochemical companies.
# Leading Low-Cost provider.